Second-generation antipsychotics (SGAPs), such as olanzapine and quetiapine, have sedative properties, and are often prescribed off-label for complaints of insomnia. These drugs carry significant risk of potential side-effects including weight gain and metabolic complications, even at low doses used to treat insomnia. In patients with dementia, they can also potentially cause serious side-effects of increased risk of cerebrovascular event and increased risk of death.
Conditions: Insomnia, Sleep Disorder, Sleeplessness
Treatments: Second-Generation Antipsychotics (SGAP), Olanzapine, Quetiapine
Sources